Pro-Dex, Inc., together with its subsidiaries, designs, develops, and manufactures powered surgical instruments, dental instruments, and rotary air motors worldwide. It also manufactures plastic injection molds for various industries; and shavers and machined parts. In addition, it provides engineering, and quality and regulatory consulting services. The company offers its products under the name of Pro-Dex.Pro-Dex, Inc. sells its medical device products primarily to original equipment manufacturers; and dental products to dental product distributors. Its products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone949-769-3200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$22.47 million
Profitability
Miscellaneous
Employees80
OptionableNot Optionable
Pro-Dex (NASDAQ:PDEX) Frequently Asked Questions
What is Pro-Dex's stock symbol?
Pro-Dex trades on the NASDAQ under the ticker symbol "PDEX."
How were Pro-Dex's earnings last quarter?
Pro-Dex Inc (NASDAQ:PDEX) issued its quarterly earnings data on Thursday, November, 8th. The medical instruments supplier reported $0.31 earnings per share (EPS) for the quarter. The medical instruments supplier had revenue of $6.92 million for the quarter. Pro-Dex had a net margin of 9.67% and a return on equity of 13.55%. View Pro-Dex's Earnings History.
When is Pro-Dex's next earnings date?
Has Pro-Dex been receiving favorable news coverage?
News stories about PDEX stock have been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Pro-Dex earned a news impact score of -1.4 on InfoTrie's scale. They also assigned press coverage about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term.
Who are some of Pro-Dex's key competitors?
Some companies that are related to Pro-Dex include Liquidia Technologies (LQDA), T2 Biosystems (TTOO), RenovaCare (RCAR), Sensus Healthcare (SRTS), RA Medical Systems (RMED), STRATA Skin Sciences (SSKN), Endologix (ELGX), iCAD (ICAD), Alphatec (ATEC), Apollo Endosurgery (APEN), Motus GI (MOTS), Arch Therapeutics (ARTH), Invo Bioscience (IVOB), Repro-Med Systems (REPR) and CAS Medical Systems (CASM).
Who are Pro-Dex's key executives?
Pro-Dex's management team includes the folowing people:
- Mr. Richard Lee Van Kirk Jr., CEO, Pres, COO & Director (Age 58)
- Mrs. Alisha K. Charlton, CFO & Corp. Sec. (Age 49)
- Mr. Phillip S. Brown, VP & GM of OMS
- Angel Rebamontan Domingo, Director of Regulatory Affairs & Quality Assurance
How do I buy shares of Pro-Dex?
Shares of PDEX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pro-Dex's stock price today?
One share of PDEX stock can currently be purchased for approximately $13.39.
How big of a company is Pro-Dex?
Pro-Dex has a market capitalization of $56.61 million and generates $22.47 million in revenue each year. Pro-Dex employs 80 workers across the globe.
What is Pro-Dex's official website?
How can I contact Pro-Dex?
Pro-Dex's mailing address is 2361 MCGAW AVENUE, IRVINE CA, 92614. The medical instruments supplier can be reached via phone at 949-769-3200 or via email at [email protected]
MarketBeat Community Rating for Pro-Dex (NASDAQ PDEX)
MarketBeat's community ratings are surveys of what our community members think about Pro-Dex and other stocks. Vote "Outperform" if you believe PDEX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PDEX will underperform the S&P 500 over the long term. You may vote once every thirty days.
